RisdiplamPneumonia following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1950卷 / 1期

关键词：

D O I：

10.1007/s40278-023-36745-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：348 / 348

相关论文

共 50 条

[41] HydroxychloroquineHaemolysis following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 376 - 376
[42] SintilimabFasciitis following off-label use: case report
Reactions Weekly, 2021, 1884 (1) : 391 - 391
[43] CeftriaxoneCholelithiasis following off-label use: case report
Reactions Weekly, 2021, 1880 (1) : 118 - 118
[44] SpironolactoneDysmenorrhoea following off-label use : case report
Reactions Weekly, 2024, 2018 (1) : 430 - 430
[45] IvabradinePhosphene following off-label use: case report
Reactions Weekly, 2019, 1769 (1) : 267 - 267
[46] OmalizumabFever following off-label use: case report
Reactions Weekly, 2019, 1773 (1) : 265 - 265
[47] DenosumabHypocalcaemia following off-label use: case report
Reactions Weekly, 2020, 1808 (1) : 108 - 108
[48] AmantadineConstipation following off-label use: case report
Reactions Weekly, 2019, 1760 (1) : 20 - 20
[49] PralatrexateStomatitis following off-label use: case report
Reactions Weekly, 2021, 1842 (1) : 309 - 309
[50] PembrolizumabHyperthyroidism following off-label use: case report
Reactions Weekly, 2017, 1643 (1) : 239 - 239

← 1 2 3 4 5 →